Crescent Biopharma announced a trial-in-progress presentation for the ASCEND study of CR-001, a PD-1 x VEGF bispecific antibody, at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The presentation will provide an update on the ongoing Phase 1/2 clinical trial evaluating CR-001 in patients with advanced solid tumors.
CR-001 is designed to simultaneously target PD-1 and VEGF, aiming to enhance anti-tumor immune response and inhibit angiogenesis. The ASCEND study is investigating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CR-001 in a dose-escalation and expansion cohort.
The ASCO 2026 Annual Meeting is scheduled to take place from June 5-9, 2026, in Chicago, Illinois. The presentation details, including the session date and time, will be announced closer to the meeting.
